SGLT2 inhibitors × kidney outcomes

SynthesisActa diabetologica2023

Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis.

Naveen C Hegde et al.PubMed ↗Publisher ↗

What the trial testedas reported · 48,067 people · 2023

Range includes no effect

No clear effect on kidney outcomes

2.3×0.7× to 3.9×

Bigger than 9 in 10 on the map

As reported

OR 2.3, 95% CI 0.72–3.90

One number in the abstract

the abstract, start to end

eGFR benefit with an odds ratio of 2.3 (CI 0.72-3.9) compared to

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
OR 2.30.72–3.90
SGLT2 inhibitorsKidney outcomes

SGLT2 inhibitors × kidney outcomeshelps?settled

unlikelylikely
0.89not counted
← favours comparatorfavours treatment →
more certainless certain
1 / 5

5 papers cite it

2023
2024
2025
2026
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 37322184